



NDA 206316/S-019

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENT**

Daiichi Sankyo, Inc.
Attention: Nicola Romano
Senior Director, Regulatory Affairs
211 Mount Airy Road
Basking Ridge, NJ 07920

Dear Nicola Romano:

Please refer to your supplemental new drug application (sNDA) dated and received December 19, 2022, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Savaysa (edoxaban) tablets.

This Prior Approval supplemental new drug application provides for changes to section 8.4 Pediatric Use in the Prescribing Information and the Medication Guide.

We have received your submission dated January 28, 2022, containing the final report for the following postmarketing requirement listed in the January 8, 2015, approval letter.

- 2852-1 Perform, complete and submit the full study report for a single-dose study of pharmacokinetics and pharmacodynamics (PK/PD) of edoxaban in pediatric patients at risk for venous thromboembolism (VTE), requiring anticoagulation or recently completing standard of care anticoagulation in accordance with your October 31, 2013 agreed upon Initial Pediatric Study Plan (iPSP).

We have also received your submission dated December 19, 2022, containing the final report for the following postmarketing requirement listed in the January 8, 2015, approval letter.

- 2852-2 Perform, complete and submit the full study report for a phase 3 multicenter, randomized, active control study of edoxaban in pediatric patients with documented venous thromboembolism in accordance with your October 31, 2013 agreed upon Initial Pediatric Study Plan (iPSP).

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

We have reviewed your submission and conclude that the above requirement (PMR 2852-1) was fulfilled.

We remind you that there is a postmarketing requirement listed in the January 8, 2015, approval letter that is still open.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call May Zuwannin, Regulatory Project Manager, at 301-796-7775.

Sincerely,

{See appended electronic signature page}

Ann Farrell, MD
Director
Division of Nonmalignant Hematology
Office of Cardiology, Hematology, Endocrinology,
and Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ANN T FARRELL
10/18/2023 08:29:24 AM